or Try an Advanced Search...

    Technical Analysis for NKGN - NKGen Biotech, Inc.

    Grade Last Price % Change Price Change
    F 1.27 0.00% 0.00
    NKGN closed unchanged on Monday, July 1, 2024, on 2 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical NKGN trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Resistance Bearish 2.42%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.42%
    Outside Day Range Expansion 2.42%
    Older End-of-Day Signals for NKGN ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance 3 days ago
    Down 3% 3 days ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry 3 days ago
    Fell Below Previous Day's Low 3 days ago
    Down 2 % 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NKGN Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immune System Stem Cell Cell Therapy Cell Biology Natural Killer Cell Lymphocytes

    Is NKGN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 12 NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
    Jun 3 NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
    May 23 NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 20 Dow Falls Over 150 Points; Sohu Posts Q1 Loss
    May 20 Nasdaq Surges 100 Points; Wix.com Shares Jump Following Q1 Results
    May 20 NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
    May 16 NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
    Apr 29 NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
    Apr 25 NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    Apr 24 NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    See more NKGN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.88
    52 Week Low 0.7802
    Average Volume 1,822,016
    200-Day Moving Average 2.60
    50-Day Moving Average 1.41
    20-Day Moving Average 1.32
    10-Day Moving Average 1.23
    Average True Range 0.13
    RSI (14) 45.95
    ADX 12.47
    +DI 20.77
    -DI 17.40
    Chandelier Exit (Long, 3 ATRs) 1.35
    Chandelier Exit (Short, 3 ATRs) 1.57
    Upper Bollinger Bands 1.53
    Lower Bollinger Band 1.11
    Percent B (%b) 0.38
    BandWidth 32.14
    MACD Line -0.06
    MACD Signal Line -0.06
    MACD Histogram -0.0006
    Fundamentals Value
    Market Cap 27.8 Million
    Num Shares 21.9 Million
    EPS -2.57
    Price-to-Earnings (P/E) Ratio -0.49
    Price-to-Sales 0.00
    Price-to-Book 0.00
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.33
    Resistance 3 (R3) 1.33 1.31 1.32
    Resistance 2 (R2) 1.31 1.29 1.31 1.32
    Resistance 1 (R1) 1.29 1.29 1.30 1.29 1.31
    Pivot Point 1.27 1.27 1.28 1.27 1.27
    Support 1 (S1) 1.25 1.25 1.26 1.25 1.23
    Support 2 (S2) 1.23 1.25 1.23 1.22
    Support 3 (S3) 1.21 1.23 1.22
    Support 4 (S4) 1.21